Loading…
China Pharma Holdings, Inc. is projected to decline to $1.05 by 2027, a -8% move from its current price of $1.14. CPHI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.9991 | $1.14 | $1.30 | -0.11% |
| Aug 6 | $0.9454 | $1.14 | $1.37 | -0.21% |
| Aug 7 | $0.9059 | $1.14 | $1.43 | -0.32% |
| Aug 8 | $0.8738 | $1.14 | $1.47 | -0.42% |
| Aug 9 | $0.8463 | $1.13 | $1.52 | -0.53% |
| Aug 10 | $0.8221 | $1.13 | $1.56 | -0.63% |
| Aug 11 | $0.8004 | $1.13 | $1.60 | -0.74% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8004 | $1.13 | $1.60 | -0.74% |
| Week 2 | $0.6884 | $1.12 | $1.83 | -1.47% |
| Week 3 | $0.6121 | $1.11 | $2.03 | -2.20% |
| Week 4 | $0.5537 | $1.11 | $2.21 | -2.92% |
| Week 5 | $0.5065 | $1.10 | $2.38 | -3.64% |
| Week 6 | $0.467 | $1.09 | $2.55 | -4.35% |
| Week 7 | $0.4331 | $1.08 | $2.70 | -5.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
China Pharma Holdings, Inc. (CPHI) is a healthcare company with a market capitalization of $44.98M and a current share price of $1.11. It is ranked 4543 by market cap among listed assets. The near-term picture shows a neutral stance, with technicals indicating a balanced setup as investors digest the latest price levels.
A major floor 54.4% below — a decisive break under it would weaken the trend.
The nearest floor, 50.0% below — buyers have tended to step in here.
The nearest ceiling, 610.5% above — a clean break opens room to run.
A major ceiling 846.5% above — clearing it would confirm fresh momentum.
Key CPHI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CPHI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.23 | Sell | $1.33 | Sell |
| MA 10 | $2.02 | Sell | $1.49 | Sell |
| MA 20 | $1.41 | Sell | $1.42 | Sell |
| MA 50 | $1.01 | Buy | $1.14 | Buy |
| MA 100 | $0.825 | Buy | $1.01 | Buy |
| MA 200 | $1.06 | Buy | $1.13 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.72 | Neutral |
| Stoch RSI (14) | 11.22 | Buy |
| CCI (20) | -26.17 | Neutral |
| Williams %R (14) | -93.32 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | 0.91 | Buy |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 6.68 | Buy |
| TRIX (15) | 3.89 | Buy |
| Awesome (5,34) | 0.11 | Buy |
| Ultimate (7,14,28) | 36.55 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 0.88 | Buy |
| ADX (14) | 12.81 | Neutral |
| ATR (14) | 0.67 | Info |
The 30-day technical picture is neutral. RSI14 sits at 50, with a SMA50 of $1.01 and a SMA200 of $1.06, reflecting modest momentum either way.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.52 | $1.14 | $1.53 | 0% | Neutral | |
| $0.7617 | $1.05 | $1.55 | -8% | Neutral | |
| $0.7531 | $1.10 | $1.74 | -4% | Neutral | |
| $0.6388 | $0.9825 | $1.63 | -14% | Neutral | |
| $0.8133 | $1.31 | $2.27 | +15% | Neutral | |
| $1.02 | $1.73 | $3.09 | +51% | Bullish | |
| $0.9302 | $1.64 | $3.02 | +44% | Bullish | |
| $0.849 | $1.56 | $2.96 | +36% | Bullish | |
| $0.7774 | $1.48 | $2.89 | +30% | Bullish | |
| $0.751 | $1.49 | $2.97 | +31% | Bullish | |
| $1.01 | $2.23 | $4.90 | +96% | Bullish | |
| $1.60 | $3.55 | $8.17 | +212% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.52 | $1.14 | $1.42 | +0.00% |
| September 2026 | $0.88 | $1.07 | $1.36 | -6.17% |
| October 2026 | $0.8397 | $1.03 | $1.34 | -3.24% |
| November 2026 | $0.891 | $1.11 | $1.46 | +7.32% |
| December 2026 | $0.9101 | $1.15 | $1.53 | +3.22% |
Click any year to see its month-by-month CPHI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CPHI could reach as high as $1.53, with a base case around $1.14 and support toward $0.52 — roughly 0% from $1.14. A consolidation phase looks the most probable path here.
Expect CPHI to range from $0.7617 to $1.55 through 2027. The $1.05 average target implies a -8% move from current prices. That is -8% versus the projected 2026 average. Price action looks broadly range-bound.
The CPHI price prediction for 2028 points to an average of $1.10 (low $0.7531, high $1.74) — a potential decline of -4% on today's $1.14. A consolidation phase looks the most probable path here.
In 2029, CPHI is projected to trade between $0.6388 and $1.63, averaging $0.9825 — a potential decline of -14% from today's $1.14. That is -11% versus the projected 2028 average. Price action looks broadly range-bound.
China Pharma Holdings, Inc.'s 2030 outlook centres on $1.31, within a $0.8133 to $2.27 range. That is up +34% on the projected 2029 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, CPHI could reach as high as $3.09, with a base case around $1.73 and support toward $1.02 — roughly +51% from $1.14. Momentum favours further upside here.
Expect CPHI to range from $0.9302 to $3.02 through 2032. The $1.64 average target implies a +44% move from current prices. That is -5% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The CPHI price prediction for 2033 points to an average of $1.56 (low $0.849, high $2.96) — a potential gain of +36% on today's $1.14. Momentum favours further upside here.
In 2034, CPHI is projected to trade between $0.7774 and $2.89, averaging $1.48 — a potential gain of +30% from today's $1.14. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
China Pharma Holdings, Inc.'s 2035 outlook centres on $1.49, within a $0.751 to $2.97 range. That is up 0% on the projected 2034 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2040, CPHI could reach as high as $4.90, with a base case around $2.23 and support toward $1.01 — roughly +96% from $1.14. Buyers look set to stay in control over this stretch.
Expect CPHI to range from $1.60 to $8.17 through 2050. The $3.55 average target implies a +212% move from current prices. That is up +59% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CPHI today (≈ 877.192982 CPHI) could be worth
$3,115.51
+$2,115.51 (+212%) by 2050 · US Dollar
Based on the average projected CPHI price of $3.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CPHIwould be worth at today's price.
$1,000 invested in CPHI on Jul 31, 2025 (≈ 584.795309 CPHI) would be worth
$666.67
-$333.33 (-33.3%) today · 0.67× · US Dollar
Based on a CPHI entry price of $1.71 vs. today's $1.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.52 | $750 | -25.0% |
| 1 month ago | $0.68 | $1,676.47 | +67.6% |
| 3 months ago | $0.53 | $2,150.94 | +115.1% |
| 6 months ago | $0.9 | $1,266.67 | +26.7% |
| 1 year ago | $1.71 | $666.67 | -33.3% |
| All time (5.0y) ago | $440 | $2.59 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CPHI forecast.
Our base-case forecast reaches $2.30 around 2050.
Implied market cap at $2.30: $93.2M
Forecasts project a mixed near-term path and a clearer longer-term upside. For 2026, the avg price is $1.11 with a min of $0.52, a max of $1.49, and ROI of 0% (sentiment NEUTRAL). In 2027, the avg is $1.02 with a min of $0.7399, a max of $1.51, and ROI of -8.5% (neutral).
2028 shows avg $1.07 (min $0.7353, max $1.70) with ROI -3.3% (neutral), and 2029 shows avg $0.9531 (min $0.6195, max $1.58) with ROI -14.1% (neutral). Beginning in 2030, the outlook improves: avg $1.28, min $0.7928, max $2.21, ROI 15.2% (neutral). The years 2031–2035 are labeled BULLISH, with 2031 avg $1.69 (ROI 52.1%), 2032 avg $1.58 (ROI 42.8%), 2033 avg $1.51 (ROI 36.2%), 2034 avg $1.45 (ROI 30.8%), and 2035 avg $1.44 (ROI 29.8%).
The longer horizon continues to rise, with 2040 avg $2.18 (ROI 96.3%) and 2050 avg $3.46 (ROI 211.4%), both labeled BULLISH. These figures represent projections and are not guarantees of future results.
Tap a question to reveal the answer.
2030 avg price is $1.28, with a min of $0.7928 and a max of $2.21, and a projected ROI of 15.2%. The forecast sentiment for 2030 is NEUTRAL.
The forecast shows a mix of near-term neutral/flat years (2026 avg $1.11, ROI 0%; 2027 avg $1.02, ROI -8.5%; 2028 avg $1.07, ROI -3.3%; 2029 avg $0.9531, ROI -14.1%), followed by meaningful upside from 2030 onward (2030 avg $1.28, ROI 15.2%; 2031 avg $1.69, ROI 52.1%; 2040 avg $2.18, ROI 96.3%; 2050 avg $3.46, ROI 211.4%). The later-years are labeled BULLISH, indicating potential upside but with notable risk in the near term.
The forecasted maximum price is $7.95 in 2050, which is below $8. Therefore, the model does not project reaching $8 in the horizon provided. The 30-day resistance level is $8.10, which is above the projected max.
Sentiment is NEUTRAL. RSI14 is 50, with SMA50 at $1.01 and SMA200 at $1.06. The 30-day price range is $0.4306 to $2.86, with a nearby support of $0.57 and a resistance of $8.10.
For 2050, the avg price is $3.46, with a min of $1.56 and a max of $7.95, and a projected ROI of 211.4%; the sentiment is BULLISH.
China Pharma Holdings, Inc. Community Discussion
0Share your China Pharma Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.